Strides Pharma Science Balance Sheet Health
Financial Health criteria checks 3/6
Strides Pharma Science has a total shareholder equity of ₹22.1B and total debt of ₹22.2B, which brings its debt-to-equity ratio to 100%. Its total assets and total liabilities are ₹59.9B and ₹37.7B respectively. Strides Pharma Science's EBIT is ₹6.7B making its interest coverage ratio 2.7. It has cash and short-term investments of ₹2.5B.
Key information
100.0%
Debt to equity ratio
₹22.15b
Debt
| Interest coverage ratio | 2.7x |
| Cash | ₹2.47b |
| Equity | ₹22.15b |
| Total liabilities | ₹37.75b |
| Total assets | ₹59.90b |
Recent financial health updates
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Financial Position Analysis
Short Term Liabilities: STAR's short term assets (₹30.9B) exceed its short term liabilities (₹29.6B).
Long Term Liabilities: STAR's short term assets (₹30.9B) exceed its long term liabilities (₹8.1B).
Debt to Equity History and Analysis
Debt Level: STAR's net debt to equity ratio (88.9%) is considered high.
Reducing Debt: STAR's debt to equity ratio has increased from 67.5% to 100% over the past 5 years.
Debt Coverage: STAR's debt is well covered by operating cash flow (36.9%).
Interest Coverage: STAR's interest payments on its debt are not well covered by EBIT (2.7x coverage).